Discontinuing combination antiretroviral therapy during the first trimester of pregnancy: insights from plasma human immunodeficiency virus-1 RNA viral load and CD4 cell count.

A. M. Bucceri, E. Somigliana, R. Matrone, C. Uberti-Foppa, P. Viganò, M. Vignali

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

OBJECTIVE: Options for human immunodeficiency virus-1-infected women who are already receiving antiretroviral medications when they become pregnant include the continuation or discontinuation of the therapy during the first trimester. These two strategies are compared in terms of plasma human immunodeficiency virus viral load and CD4 cell count. STUDY DESIGN: Seventy women who attended the II Department of Obstetrics and Gynecology were identified. Four different periods for laboratory evaluations were decided: presuspension, suspension, second trimester, and third trimester. RESULTS: Thirty-two women (46%) discontinued antiretroviral therapy; 38 women (54%) did not. Whereas plasma HIV virus viral load and CD4 cell count did not significantly vary during pregnancy in patients who did not interrupt the therapy, these two variables were influenced significantly by the discontinuation of treatment (P

Original languageEnglish
Pages (from-to)545-551
Number of pages7
JournalAmerican Journal of Obstetrics and Gynecology
Volume189
Issue number2
Publication statusPublished - Aug 2003

Fingerprint

First Pregnancy Trimester
CD4 Lymphocyte Count
Viral Load
HIV-1
RNA
HIV
Hospital Obstetrics and Gynecology Department
Third Pregnancy Trimester
Second Pregnancy Trimester
Therapeutics
Gynecology
Suspensions
Viruses
Pregnancy

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynaecology

Cite this

@article{6bf6e40921fe44509fb7812d73a4151b,
title = "Discontinuing combination antiretroviral therapy during the first trimester of pregnancy: insights from plasma human immunodeficiency virus-1 RNA viral load and CD4 cell count.",
abstract = "OBJECTIVE: Options for human immunodeficiency virus-1-infected women who are already receiving antiretroviral medications when they become pregnant include the continuation or discontinuation of the therapy during the first trimester. These two strategies are compared in terms of plasma human immunodeficiency virus viral load and CD4 cell count. STUDY DESIGN: Seventy women who attended the II Department of Obstetrics and Gynecology were identified. Four different periods for laboratory evaluations were decided: presuspension, suspension, second trimester, and third trimester. RESULTS: Thirty-two women (46{\%}) discontinued antiretroviral therapy; 38 women (54{\%}) did not. Whereas plasma HIV virus viral load and CD4 cell count did not significantly vary during pregnancy in patients who did not interrupt the therapy, these two variables were influenced significantly by the discontinuation of treatment (P",
author = "Bucceri, {A. M.} and E. Somigliana and R. Matrone and C. Uberti-Foppa and P. Vigan{\`o} and M. Vignali",
year = "2003",
month = "8",
language = "English",
volume = "189",
pages = "545--551",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Discontinuing combination antiretroviral therapy during the first trimester of pregnancy

T2 - insights from plasma human immunodeficiency virus-1 RNA viral load and CD4 cell count.

AU - Bucceri, A. M.

AU - Somigliana, E.

AU - Matrone, R.

AU - Uberti-Foppa, C.

AU - Viganò, P.

AU - Vignali, M.

PY - 2003/8

Y1 - 2003/8

N2 - OBJECTIVE: Options for human immunodeficiency virus-1-infected women who are already receiving antiretroviral medications when they become pregnant include the continuation or discontinuation of the therapy during the first trimester. These two strategies are compared in terms of plasma human immunodeficiency virus viral load and CD4 cell count. STUDY DESIGN: Seventy women who attended the II Department of Obstetrics and Gynecology were identified. Four different periods for laboratory evaluations were decided: presuspension, suspension, second trimester, and third trimester. RESULTS: Thirty-two women (46%) discontinued antiretroviral therapy; 38 women (54%) did not. Whereas plasma HIV virus viral load and CD4 cell count did not significantly vary during pregnancy in patients who did not interrupt the therapy, these two variables were influenced significantly by the discontinuation of treatment (P

AB - OBJECTIVE: Options for human immunodeficiency virus-1-infected women who are already receiving antiretroviral medications when they become pregnant include the continuation or discontinuation of the therapy during the first trimester. These two strategies are compared in terms of plasma human immunodeficiency virus viral load and CD4 cell count. STUDY DESIGN: Seventy women who attended the II Department of Obstetrics and Gynecology were identified. Four different periods for laboratory evaluations were decided: presuspension, suspension, second trimester, and third trimester. RESULTS: Thirty-two women (46%) discontinued antiretroviral therapy; 38 women (54%) did not. Whereas plasma HIV virus viral load and CD4 cell count did not significantly vary during pregnancy in patients who did not interrupt the therapy, these two variables were influenced significantly by the discontinuation of treatment (P

UR - http://www.scopus.com/inward/record.url?scp=0142024887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142024887&partnerID=8YFLogxK

M3 - Article

C2 - 14520232

AN - SCOPUS:0142024887

VL - 189

SP - 545

EP - 551

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 2

ER -